Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Veracyte (VCYT) over the last 10 years, with Q2 2025 value amounting to $20.5 million.

  • Veracyte's Asset Writedowns and Impairment changed N/A to $20.5 million in Q2 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year decrease of 2876.92%. This contributed to the annual value of $3.4 million for FY2024, which is 9507.23% down from last year.
  • Veracyte's Asset Writedowns and Impairment amounted to $20.5 million in Q2 2025.
  • Veracyte's Asset Writedowns and Impairment's 5-year high stood at $34.9 million during Q3 2023, with a 5-year trough of $185000.0 in Q3 2024.
  • For the 4-year period, Veracyte's Asset Writedowns and Impairment averaged around $11.9 million, with its median value being $3.0 million (2022).
  • Over the last 5 years, Veracyte's Asset Writedowns and Impairment had its largest YoY gain of 6957.45% in 2024, and its largest YoY loss of 9946.99% in 2024.
  • Over the past 4 years, Veracyte's Asset Writedowns and Impairment (Quarter) stood at $3.3 million in 2022, then surged by 865.61% to $32.0 million in 2023, then tumbled by 91.4% to $2.8 million in 2024, then soared by 644.55% to $20.5 million in 2025.
  • Its Asset Writedowns and Impairment stands at $20.5 million for Q2 2025, versus $2.8 million for Q4 2024 and $185000.0 for Q3 2024.